Literature DB >> 11775243

Gene mutation in patients with primary open-angle glaucoma in a pedigree in China.

J Ge1, Y Zhuo, Y Guo, W Ming, W Yin.   

Abstract

OBJECTIVE: To investigate the genetic basis of the pathogenesis of a Guangzhou (GZ.1) pedigree with primary open-angle glaucoma (POAG).
METHODS: DNA fragments of the trabecular meshwork inducible glucocorticoid response protein (TIGR) gene from 4 typical POAG patients and 2 normal subjects were amplified by polymerase chain reaction (PCR). The amplified PCR fragment was cloned into a pT-Adv vector, and direct sequencing was carried out on an ABI-373 automated DNA sequencer using dyeterminator chemistry to detect the mutation.
RESULTS: The TIGR gene mutation was identified in the selected subjects of this pedigree. This mutation is a "C-to-T" transition at position 370, different from that of western countries and equivalent to the position change found in Japanese patients with familial POAG. No mutation was found in the TIGR gene fragment in 2 normal subjects of the pedigree.
CONCLUSIONS: These preliminary results provide insights into the pathogenesis of POAG by the TIGR gene mutation, and into the underlying action of the different mutations in oriental and western peoples.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11775243

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  9 in total

1.  The stem cell and tissue engineering research in Chinese ophthalmology.

Authors:  Jian Ge; Jingbo Liu
Journal:  Front Med China       Date:  2007-02-01

Review 2.  Current concepts on primary open-angle glaucoma genetics: a contribution to disease pathophysiology and future treatment.

Authors:  M Gemenetzi; Y Yang; A J Lotery
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

3.  Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.

Authors:  Amirthaa Suntharalingam; Jose F Abisambra; John C O'Leary; John Koren; Bo Zhang; Myung Kuk Joe; Laura J Blair; Shannon E Hill; Umesh K Jinwal; Matthew Cockman; Adam S Duerfeldt; Stanislav Tomarev; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

4.  Sequence analysis of MYOC and CYP1B1 in a Chinese pedigree of juvenile glaucoma with goniodysgenesis.

Authors:  Xiaoming Chen; Naihong Yan; Hongmin Yun; Jingjing Sun; Man Yu; Jiumo Zhou; Guiqun Cao; Hongbo Yin; Mao Li; Xuyang Liu
Journal:  Mol Vis       Date:  2009-08-07       Impact factor: 2.367

5.  New mutation in the MYOC gene and its association with primary open-angle glaucoma in a Chinese family.

Authors:  Xiying Qu; Xin Zhou; Keyuan Zhou; Xiaobin Xie; Yanli Tian
Journal:  Mol Biol Rep       Date:  2009-08-18       Impact factor: 2.316

6.  A novel MYOC heterozygous mutation identified in a Chinese Uygur pedigree with primary open-angle glaucoma.

Authors:  Su-ping Cai; Paerheti Muhemaiti; Yan Yin; Hongbo Cheng; A Di Ya; Maliyamu Keyimu; Xu Cao; Ning Fan; Liqiong Jiang; Naihong Yan; Xiaomin Zhou; Yun Wang; Xuyang Liu
Journal:  Mol Vis       Date:  2012-07-18       Impact factor: 2.367

7.  Identification of Mutations in Myocilin and Beta-1,4-galactosyltransferase 3 Genes in a Chinese Family with Primary Open-angle Glaucoma.

Authors:  Rong-Feng Liao; Zi-Lin Zhong; Min-Jie Ye; Li-Yun Han; Dong-Qing Ye; Jian-Jun Chen
Journal:  Chin Med J (Engl)       Date:  2016-12-05       Impact factor: 2.628

8.  Pro370Leu mutant myocilin impairs mitochondrial functions in human trabecular meshwork cells.

Authors:  Yuan He; Kar Wah Leung; Ye-Hong Zhuo; Jian Ge
Journal:  Mol Vis       Date:  2009-04-23       Impact factor: 2.367

9.  Pro370Leu mutant myocilin disturbs the endoplasm reticulum stress response and mitochondrial membrane potential in human trabecular meshwork cells.

Authors:  Lina Wang; Yehong Zhuo; Bingqian Liu; Shengsong Huang; Fei Hou; Jian Ge
Journal:  Mol Vis       Date:  2007-04-19       Impact factor: 2.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.